Alnylam Pharmaceuticals: Funding, Investors & Team (Oct 2026)
Alnylam is the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases.
Alnylam Pharmaceuticals has raised $900M across 1 funding round on record, the most recent a Post-IPO Debt of $900M announced in Sep 2022.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Alnylam Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: Sep 2022.
Alnylam Pharmaceuticals Funding Rounds
Alnylam Pharmaceuticals Founders and Leadership Team
No contact details are on record for this team yet.
Alnylam Pharmaceuticals Funding Compared to Other Biotechnology Startups
Alnylam Pharmaceuticals' latest round of $900M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Alnylam Pharmaceuticals in Biotechnology and Cambridge
Companies Similar to Alnylam Pharmaceuticals
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Alnylam Pharmaceuticals Funding FAQs
What does Alnylam Pharmaceuticals do?
Alnylam is the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases.
How much funding has Alnylam Pharmaceuticals raised?
Alnylam Pharmaceuticals has raised $900M across 1 round on record. The most recent is a Post-IPO Debt of $900M announced in Sep 2022.
When did Alnylam Pharmaceuticals last raise funding?
Alnylam Pharmaceuticals' most recent funding round on record is a Post-IPO Debt of $900M, announced in Sep 2022.
Who founded Alnylam Pharmaceuticals?
FundedIQ lists David Bartel (Founder) at Alnylam Pharmaceuticals.
Where is Alnylam Pharmaceuticals headquartered?
Alnylam Pharmaceuticals is based in Cambridge, Massachusetts, United States.
How many employees does Alnylam Pharmaceuticals have?
Alnylam Pharmaceuticals is in the 1001-5000 employee band.
How does Alnylam Pharmaceuticals' funding compare to other Biotechnology startups?
Alnylam Pharmaceuticals' latest round of $900M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Alnylam Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Alnylam Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.